1. Sci Rep. 2024 Nov 27;14(1):29515. doi: 10.1038/s41598-024-79340-z.

Development of an efficient NUPR1 inhibitor with anticancer activity.

Liu X(#)(1), Jimenez-Alesanco A(#)(2), Li Z(3), Rizzuti B(2)(4), Neira JL(2)(5), 
Estaras M(1), Peng L(6), Chuluyan E(7)(8), Garona J(9)(10), Gottardo F(9)(10), 
Velazquez-Campoy A(2)(11)(12)(13), Xia Y(3), Abian O(2)(11)(12)(13), 
Santofimia-Castaño P(14), Iovanna J(15)(16)(17).

Author information:
(1)Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS 
UMR7258, Aix Marseille Université and Institut Paoli Calmettes, Parc 
Scientifique etTechnologique de Luminy, Equipe labéliséeLigue Nationale contre 
le cancer, 163 Avenue de Luminy, 13288, Marseille, France.
(2)Instituto de Biocomputación y Física de Sistemas Complejos (BIFI), 50018, 
Zaragoza, Spain.
(3)Chongqing Key Lab oratory of Natural Product Synthesis and Drug Research, 
School ofPharmaceutical Sciences, Chongqing University, No.55 Daxuecheng South 
Road, Chongqing, 401331, People's Republic of China.
(4)CNR NANOTEC, SS Rende (CS), Department of Physics, University of Calabria, 
Via P.Bucci, Cubo 31 C, 87036, Rende, Italy.
(5)IDIBE, Universidad Miguel Hernández, Edificio Torregaitán, Avda. del 
Ferrocarril s/n, 03202, Elche, Alicante, Spain.
(6)Aix Marseille Université, CNRS, Centre Interdisciplinaire de Nanoscience de 
Marseille, UMR7325, Parc Scientifique et Technologique de Luminy, Equipe 
labélisée Ligue Nationale contre le cancer, 163 Avenue de Luminy, 13288, 
Marseille, France.
(7)Center for Pharmacological and Botanical Studies, Faculty of Medicine, 
National Council for Scientific and Technical Research, Buenos Aires University, 
C1121ABG, Buenos Aires, Argentina.
(8)Department of Microbiology, Parasitology and Immunology, Faculty of Medicine, 
Buenos Aires University, C1121ABG, Buenos Aires, Argentina.
(9)Hospital de Alta Complejidad El Cruce, Florencio Varela, Buenos Aires, 
Argentina.
(10)University Arturo Jauretche, Florencio Varela, Buenos Aires, Argentina.
(11)Aragon Institute for Health Research (IIS Aragon), Zaragoza, Spain.
(12)Centro de Investigación Biomédica en Red en el Área Temática de Enfe 
rmedadesHepáticas y Digestivas (CIBERehd), Madrid, Spain.
(13)Departamento de Bioquímica y Biología Molecular y Celular, Universidad de 
Zaragoza, Zaragoza, Spain.
(14)Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS 
UMR7258, Aix Marseille Université and Institut Paoli Calmettes, Parc 
Scientifique etTechnologique de Luminy, Equipe labéliséeLigue Nationale contre 
le cancer, 163 Avenue de Luminy, 13288, Marseille, France. 
patricia.santofimia@inserm.fr.
(15)Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS 
UMR7258, Aix Marseille Université and Institut Paoli Calmettes, Parc 
Scientifique etTechnologique de Luminy, Equipe labéliséeLigue Nationale contre 
le cancer, 163 Avenue de Luminy, 13288, Marseille, France. 
juan.iovanna@inserm.fr.
(16)Hospital de Alta Complejidad El Cruce, Florencio Varela, Buenos Aires, 
Argentina. juan.iovanna@inserm.fr.
(17)University Arturo Jauretche, Florencio Varela, Buenos Aires, Argentina. 
juan.iovanna@inserm.fr.
(#)Contributed equally

Pancreatic cancer is highly lethal and has limited treatment options available. 
Our team had previously developed ZZW-115, a promising drug candidate that 
targets the nuclear protein 1 (NUPR1), which is involved in pancreatic cancer 
development and progression. However, clinical translation of ZZW-115 was 
hindered due to potential cardiotoxicity caused by its interaction with the 
human Ether-à-go-go-Related Gene (hERG) potassium channel. To address this, we 
have performed a high-throughput screening of 10,000 compounds from the 
HitFinder Chemical Library, and identified AJO14 as a lead compound that binds 
to NUPR1, without having favorable affinity towards hERG. AJO14 induced cell 
death through apoptosis, necroptosis, and parthanatos (induced by the poly-ADP 
ribose polymerase (PARP) overactivation), driven by mitochondrial catastrophe 
and decreased ATP production. This process seemed to be mediated by the 
hyperPARylation (an excessive modification of proteins by PARP, leading to 
cellular dysfunction), as it could be reversed by Olaparib, a PARP inhibitor. In 
xenografted mice, AJO14 demonstrated a dose-dependent tumor reduction activity. 
Furthermore, we attempted to improve the anti-cancer properties of AJO14 by 
molecular modification of the lead compound. Among the 51 candidates obtained 
and tested, 8 compounds exhibited a significant increase in efficacy and have 
been retained for further studies, especially LZX-2-73. These AJO14-derived 
compounds offer potent NUPR1 inhibition for pancreatic cancer treatment, without 
cardiotoxicity concerns.

© 2024. The Author(s).

DOI: 10.1038/s41598-024-79340-z
PMID: 39604425 [Indexed for MEDLINE]

Conflict of interest statement: Declarations. Competing interests: The authors 
declare no competing interests. Ethical approval and consent to participate: All 
animal care and experimental procedures were performed in agreement with the 
Animal Ethics Committee of Marseille number 14 (C2EA-14). Approval Number: 
202011181636926.